Deanna Kornacki
Research Subjects
Deanna Kornacki has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Azra Raza
Division of Hematology/Oncology, Department of Medicine, Columbia University Irving Medical Center, New York, USA
1 shared publication - Carole B. Miller
Saint Agnes Cancer Institute, Baltimore, MD
1 shared publication Elise A. Olsen
Department of Dermatology and Medicine, Duke University Medical Center, Durham, North Carolina
1 shared publication- Elizabeth O. Hexner
Abramson Cancer Center at the University of Pennsylvania, 3400 Civic Center Blvd., PCAM 2 West Pavilion, Philadelphia, PA, 19104, USA
1 shared publication - Elliott F. Winton
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA
1 shared publication - Hagop M. Kantarjian
Department of Leukemia The University of Texas, MD Anderson Cancer Center Houston Texas USA
1 shared publication
Latest Publications
- 23 September 2022
- Published by Morressier GmbH
ESDR051 - Clinical Serum Biomarker Profiling in TRuE-V1 and TRuE-V2 Vitiligo Studies After Treatment With Ruxolitinib Cream
Ruxolitinib cream was developed as a topical treatment for immune-mediated skin diseases, including vitiligo. Ruxolitinib is an equipotent inhibi | POSTER
- 23 September 2022
- Published by Morressier GmbH
ESDR051 - Clinical Serum Biomarker Profiling in TRuE-V1 and TRuE-V2 Vitiligo Studies After Treatment With Ruxolitinib Cream
Ruxolitinib cream was developed as a topical treatment for immune-mediated skin diseases, including vitiligo. Ruxolitinib is an equipotent inhibi | POSTER
- 1 February 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (2) , 412-419
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
- 1 February 2020
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 82 (2) , 412-419
Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled phase 2 study
- Top Cited PapersOpen Access
- 22 February 2017
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-14
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis-approved therapy—reduced splenomegaly and prolonged overall survival versus placebo. Here, we present the final 5-year results. Patients managed in Australia, Canada, and the USA were randomized centrally (interactive voice response system) 1:1 to oral ruxolitinib twice daily (15 or 20 mg per baseline platelet counts) or placebo. Investigators and patients were blinded to treatment. The secondary endpoints evaluated in this analysis were durability of a ≥35% reduction from baseline in spleen volume (spleen response) and overall survival, evaluated in the intent-to-treat population. Safety was evaluated in patients who received study treatment. Patients were randomized (September 2009–April 2010) to ruxolitinib (n = 155) or placebo (n = 154). At termination, 27.7% of ruxolitinib-randomized patients and 25.2% (28/111) who crossed over from placebo were on treatment; no patients remained on placebo. Patients randomized to ruxolitinib had a median spleen response duration of 168.3 weeks and prolonged median overall survival versus placebo (ruxolitinib group, not reached; placebo group, 200 weeks; HR, 0.69; 95% CI, 0.50–0.96; P = 0.025) despite the crossover to ruxolitinib. The ruxolitinib safety profile remained consistent with previous analyses. The most common new-onset all-grade nonhematologic adverse events starting <12 versus ≥48 months after ruxolitinib initiation were fatigue (29.0 vs 33.3%) and diarrhea (27.8 vs 14.6%). New-onset grade 3 or 4 anemia and thrombocytopenia both primarily occurred within the first 6 months, with no cases after 42 months. The most common treatment-emergent adverse event-related deaths in the ruxolitinib-randomized group were sepsis (2.6%), disease progression (1.9%), and pneumonia (1.9%). The final COMFORT-I results continue to support ruxolitinib as an effective treatment for patients with intermediate-2/high-risk MF. ClinicalTrials.gov, NCT00952289
- 22 February 2017
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 10 (1) , 1-14
Top Cited PapersOpen AccessLong-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. The primary and planned 3-year analyses of COMFORT-I data demonstrated that ruxolitinib—the first myelofibrosis-approved therapy—reduced splenomegaly and prolonged overall survival versus placebo. Here, we present the final 5-year results. Patients managed in Australia, Canada, and the USA were randomized centrally (interactive voice response system) 1:1 to oral ruxolitinib twice daily (15 or 20 mg per baseline platelet counts) or placebo. Investigators and patients were blinded to treatment. The secondary endpoints evaluated in this analysis were durability of a ≥35% reduction from baseline in spleen volume (spleen response) and overall survival, evaluated in the intent-to-treat population. Safety was evaluated in patients who received study treatment. Patients were randomized (September 2009–April 2010) to ruxolitinib (n = 155) or placebo (n = 154). At termination, 27.7% of ruxolitinib-randomized patients and 25.2% (28/111) who crossed over from placebo were on treatment; no patients remained on placebo. Patients randomized to ruxolitinib had a median spleen response duration of 168.3 weeks and prolonged median overall survival versus placebo (ruxolitinib group, not reached; placebo group, 200 weeks; HR, 0.69; 95% CI, 0.50–0.96; P = 0.025) despite the crossover to ruxolitinib. The ruxolitinib safety profile remained consistent with previous analyses. The most common new-onset all-grade nonhematologic adverse events starting <12 versus ≥48 months after ruxolitinib initiation were fatigue (29.0 vs 33.3%) and diarrhea (27.8 vs 14.6%). New-onset grade 3 or 4 anemia and thrombocytopenia both primarily occurred within the first 6 months, with no cases after 42 months. The most common treatment-emergent adverse event-related deaths in the ruxolitinib-randomized group were sepsis (2.6%), disease progression (1.9%), and pneumonia (1.9%). The final COMFORT-I results continue to support ruxolitinib as an effective treatment for patients with intermediate-2/high-risk MF. ClinicalTrials.gov, NCT00952289